Silo Pharma, Inc.
Silo Pharma, Inc. is a U.S.-based developmental-stage biopharmaceutical company focused on licensing, developing, and advancing drug candidates for central nervous system and stress-related disorders. Its pipeline includes intranasal, implantable, and peptide-based programs, and the company also holds digital assets as part of a treasury strategy.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment-stage drug candidates targeting PTSD, anxiety, fibromyalgia, and CNS disorders.
Intranasal and other delivery mechanisms used to improve targeting and onset of action.
Exclusive and option-based rights to external inventions and patents supporting the pipeline.
Cryptocurrency holdings and related treasury activities outside the core therapeutics business.
Customers
Silo Pharma does not sell commercial medicines at scale; its economic counterparties are primarily licensors, research institutions, and development partners that provide intellectual property, technology, or sponsored research support. If its programs advance, the eventual end customers would be patients and healthcare providers in neurology, psychiatry, pain management, and related specialty care.
Provide patents, compounds, or delivery technologies that Silo licenses to build its pipeline.
Support preclinical, toxicology, and regulatory-enabling studies for candidate advancement.
Patients with PTSD, stress-induced anxiety, fibromyalgia, Alzheimer’s disease, or neuroinflammatory conditions who would use approved products.
Psychiatrists, neurologists, pain specialists, and other clinicians who would prescribe or administer therapies.
Strategy
Silo Pharma’s strategy is to license or acquire external intellectual property, fund development, and advance a small number of differentiated CNS and pain programs toward regulatory milestones. It is also building a cryptocurrency treasury strategy, which adds a separate capital-allocation track alongside the therapeutics pipeline.
SPC-15 is the lead program and the clearest path to a clinical-stage asset.
Multiple programs reduce dependence on a single asset and expand optionality.
The company relies on external inventions to source differentiated candidates.
The treasury strategy creates a separate investment framework and capital use case.
Geography
Silo Pharma is headquartered in the United States and conducts its business through U.S.-based corporate, regulatory, and research activities. Its development programs are global in scope because the company licenses intellectual property from external parties and seeks worldwide rights for some assets, but the disclosed operating footprint is primarily U.S.-centric.
Risks
Silo Pharma faces the typical risks of a development-stage biotech company: clinical, regulatory, and intellectual property execution risk, with no assurance that its programs will reach approval or commercialization. The added cryptocurrency treasury strategy introduces market, custody, and execution risk, while the company’s small scale and Nasdaq listing dependence can affect financing flexibility and investor liquidity.
- Cryptocurrency market and treasury execution riskImpact: HighLikelihood: Medium
Digital assets can be volatile and operational mistakes in custody or trading can create losses.
Exposure - Pipeline development and regulatory riskImpact: High
Drug candidates must clear preclinical, IND, and clinical hurdles before commercialization.
Exposure - Intellectual property and licensing dependenceImpact: High
The business depends on rights from third parties and may face renewal, scope, or royalty constraints.
Exposure - Nasdaq listing and financing riskImpact: MediumLikelihood: Low
Maintaining exchange listing supports liquidity and access to capital for a pre-revenue biotech.
Exposure: Common stock market access
- Competition in CNS and psychedelic medicineImpact: Medium
Other developers are pursuing similar indications, delivery methods, and assets.
Exposure
Accounting
Judgemental itemsClinical and preclinical costs are expensed as incurred, so timing of project spend directly affects earnings.
Impact: Can create volatility in quarterly operating results
Equity awards to employees, directors, and non-employees require fair value estimation and vesting-period recognition.
Impact: Affects operating expenses and diluted share count
Revenue from the Aikido License and Sublicense Agreement is recognized over a 15-year term.
Impact: Produces small, deferred revenue recognition rather than upfront sales
Treasury holdings in crypto can introduce realized and unrealized gains or losses and valuation complexity.
Impact: Can materially affect other income and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
Solana Co
HSDT · Finance Services
Solana Co is a U.S.-based public company organized around a Solana digital asset treasury strategy, with Solana (SOL) as its primary treasury reserve asset.
Silexion Therapeutics Corp
SLXNW · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026